Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer-Reference-Cited by-同舟云学术

Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer

Published:2018-03-26 Issue:6 Volume:7 Page:2288-2298
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Holmes Frankie Ann¹²^ORCID,Hellerstedt Beth A.¹³,Pippen John E.¹⁴,Vukelja Svetislava J.¹⁵,Collea Rufus P.¹⁶,Kocs Darren M.¹⁷,Blum Joanne L.¹⁴,McIntyre Kristi J.¹⁸,Barve Minal A.¹⁸,Brooks Barry D.¹⁹,Osborne Cynthia R.¹⁴,Wang Yunfei¹,Asmar Lina¹,O'Shaughnessy Joyce¹⁴

Affiliation:

1. US Oncology Research; McKesson Specialty Health; The Woodlands Texas

2. Texas Oncology-Houston Memorial City; Houston Texas

3. Texas Oncology-Austin Central; Austin Texas

4. Texas Oncology-Baylor Sammons Cancer Center; Dallas Texas

5. Texas Oncology; Tyler Texas

6. New York Oncology Hematology; Albany New York

7. Texas Oncology; Round Rock Texas

8. Texas Oncology; Dallas Presbyterian Hospital; Dallas Texas

9. Texas Oncology; Medical City Dallas; Dallas Texas

Funder

Roche Laboratories, Inc